CASE PRESENTATION {#s1}
=================

A 66-yr-old woman without significant comorbidities was diagnosed with metastatic adenocarcinoma of the right lung including ipsilateral pleural and diffuse bone spread (T2N0M1c). Initial treatment with carboplatin/pemetrexed chemotherapy resulted in a partial remission after two cycles and was followed by pemetrexed maintenance. Meanwhile, an *ALK* rearrangement was detected by fluorescence in situ hybridization (FISH). Subsequent RNA next-generation sequencing (NGS) of the tumor identified transcripts of *KLC1* exon 9 fused with *ALK* exon 20 (K9--A20). Retrospective targeted deep sequencing of circulating tumor DNA (ctDNA) from several longitudinal blood plasma samples collected at different time points confirmed the translocation and identified the DNA breakpoints in *KLC1* intron 9 and *ALK* intron 19 ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}A). The first plasma sample, collected at the time of partial remission after two cycles of carboplatin/pemetrexed chemotherapy, showed a variant allele frequency (VAF) of 0.09% for the *ALK* fusion and no single-nucleotide variants (SNVs) in the *ALK* gene ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}B). Analysis of a simultaneously collected serum sample revealed a low abundance of CEA (39.52 ng/µL) and CYFRA 21--1 (0.53 ng/µL; [Fig. 1](#MCS004630DIEF1){ref-type="fig"}C). Two months after initiation of pemetrexed maintenance, the progression of the primary tumor and pleural effusion was noted by chest CT ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}D, I1), and new cerebral metastases were detected by brain MRI ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}D, I2). At this timepoint, the retrospectively determined *KLC1--ALK* fusion VAF rose to 6.25% and the tumor protein markers CEA, CYFRA 21--1 were also increased. Second-line treatment with crizotinib (250 bid) was initiated, and the patient initially responded with tumor shrinkage of ∼40%, as determined by radiological imaging ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}D, I3). During the next disease progression with multiple new brain lesions 50 d later ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}D, I4), the fusion VAF in retrospective analysis was 4.4% (i.e., lower than at the time of the previous systemic progression). However, four distinct secondary mutations in the kinase domain of the *ALK* gene were identified in ctDNA: *ALK* p.F1174C (c.35221T\>G) with 0.08% VAF, *ALK* p.F1174L (c.3522C\>G with 0.88% VAF and c.3522C\>A with 0.24% VAF), and *ALK* p.G1269A (c.3806G\>C) with 0.18% VAF ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}B). After whole-brain radiotherapy with 30 Gy (10 fractions of 3 Gy), clinical and radiological follow-up during the following three months indicated stable disease, wherefore crizotinib treatment was continued. However, a plasma sample taken only 3 wk after the last radiation dose retrospectively revealed rising VAFs of the fusion *KLC1--ALK* (8.01%) and all four secondary *ALK* variants, the most abundant of which was *ALK* p.F1174 (c.3522C\>G with 3.26% VAF; [Fig. 1](#MCS004630DIEF1){ref-type="fig"}B). At the same time, CEA and CYFRA 21--1 concentrations were also elevated ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}C). In accordance with the rising VAFs and protein levels, and despite the apparently stable radiologic findings, multilocular disease progression occurred just 1 mo later, with multiple new lung and bone metastases as confirmed by PET-CT. Retrospective molecular reassessment with liquid biopsy at that time point showed steadily high VAFs, whereas concentrations of protein markers rose further (CEA: \>155 ng/µL, CYFRA 21--2: \>200 ng/µL; [Fig. 1](#MCS004630DIEF1){ref-type="fig"}B,C). Based on the radiologic progression, crizotinib treatment was discontinued and a switch to ceritinib was planned, but the patient died before the therapy could be started. We also performed retrospective shallow whole-genome sequencing (sWGS) of ctDNA from a plasma sample after two cycles of carboplatin/pemetrexed and from the last sample upon progression under crizotinib. Although sWGS of ctDNA during the first months after diagnosis revealed no copy-number variations (CNVs) with a trimmed median absolute deviation from copy-number neutrality (t-MAD) of 0.0098, noticeable alterations were detected at the end of the treatment (t-MAD = 0.0414), including an amplification of the region encompassing the TP53 regulator *MDM2* on Chromosome 12 ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}C,E).

![(*A*) Schematic of the predicted genomic translocation of *KLC1*--*ALK* and aligned ctDNA reads in IGV spanning the rearrangement of *KLC1* intron 8 and *ALK* intron 19. (*B*) Kinetics of mutated allele frequencies detected in ctDNA during treatment. Corresponding images (I1--I4) are shown in *E*. Phases of stable disease and progressive disease are indicated on *top*. (*C*) Kinetics of serum protein concentrations during treatment. Corresponding images (I1--I4) are shown in *D*. Phases of stable disease and progressive disease are indicated on *top*. (*D*) Corresponding chest CT of the primary tumor (on the *left*; I1, I3) and brain MRI images of cerebral metastases (on the *right*; I2, I4) taken during the therapy course. (*E*) Copy-number profiles of Chromosome 12 from sWGS of ctDNA. The *upper* panel shows the CNV profile before crizotinib treatment initiation; the *bottom* panel shows the CNV profile at the end of treatment. (SD) Stable disease, (PD) progressive disease, (CTx) chemotherapy, (RTx) whole-brain radiotherapy.](MCS004630Die_F1){#MCS004630DIEF1}

TECHNICAL ANALYSIS AND METHODS {#s2}
==============================

The histological diagnosis of lung adenocarcinoma was performed by experienced pulmonary pathologists on a formalin-fixed and paraffin-embedded (FFPE) biopsy of the primary tumor. The presence of the *ALK* rearrangement was determined by fluorescent in situ hybridization (FISH) using ALK break-apart probes (ZytoLight SPEC ALK probe, ZytoVision). A fusion transcript with exon 9 of *KLC1* fused to *ALK* exon 20 (K9--A20) was confirmed by RNA NGS using the AmpliSeq RNA Lung Cancer Fusion Panel (Thermo Fisher Scientific) as described previously ([@MCS004630DIEC20]; [@MCS004630DIEC26]).

For ctDNA analysis, plasma was isolated from blood samples, centrifuged within 30 min of collection, and processed with the AVENIO ctDNA Analysis Kit according to the manufacturer\'s instructions (Roche Diagnostics). Briefly, cell-free DNA was isolated from 2 mL of plasma using the AVENIO cfDNA Isolation Kit (Roche) and quantified with the Qubit dsDNA High Sensitivity Kit (Thermo Fisher). Targeted sequencing libraries were prepared from 39.9 ng DNA in median (range 24.5--50 ng) using the AVENIO ctDNA Library Preparation Kit with the AVENIO Targeted and Surveillance Panel (both from Roche) for hybridization-based enrichment of a 17-gene (81-kb) and a 197-gene (198-kb) panel, respectively. Among their target regions, both panels are designed to capture the exons 19 to 28 as well as intron 19 of the *ALK* gene. CtDNA libraries from all plasma samples were initially enriched and sequenced with the AVENIO Targeted panel. To validate variants detected with the Targeted panel and to potentially identify further mutations in an extended genomic target region, all plasma samples were repeatedly enriched and sequenced with the AVENIO Surveillance panel. All protocols were conducted according to the manufacturer\'s recommendations. Enriched libraries were sequenced on an Illumina NextSeq550 using the High Output Kit V2 (300 cycles) according to the manufacturer\'s protocol (Illumina) with a median unique target sequence coverage of 7760× (range 4177×--10,869×). Automated raw data processing and data analysis was performed with the AVENIO ctDNA analysis software (Roche). Manual QC of called variants and visualization of aligned reads spanning the DNA breakpoints in *KLC1* intron 9 and *ALK* intron 19 was done using the Integrative Genomics Viewer (IGV) ([@MCS004630DIEC22]).

For low-coverage sWGS, sequencing libraries were prepared from 2.5 ng cell-free DNA using the KAPA Hyper Prep Kit with KAPA Dual-Indexed Adapters for Illumina platforms (both Roche). Following sequencing adapter ligation for 15 h at 16°C to achieve high ligation efficiency, libraries were amplified in 11 PCR cycles and purified according to the manufacturer\'s protocol. Samples were sequenced in a multiplex of 48 sWGS libraries per lane on an Illumina HiSeq4000 with 100-bp paired-end reads (Illumina). Raw sequencing reads were processed and aligned using the automated pipeline OTP ([@MCS004630DIEC21]). Genome-wide copy number profiles were estimated from low-coverage sWGS data of ctDNA using ichorCNA ([@MCS004630DIEC2]), and t-MAD scores were calculated to quantify CNVs ([@MCS004630DIEC18]).

For protein analysis, serum was isolated from blood samples and centrifuged 30 min after collection to ensure complete coagulation. Serum CEA and CYFRA 21--1 levels were determined from 10 µL of serum by multiplexed flow cytometry using the MILLIPLEX MAP Human Circulating Cancer Biomarker Magnetic Bead Panel (Merck) with the Luminex Bio-Plex 200 immunoassay platform (Bio-Rad). All protocols were conducted according to the manufacturer\'s recommendations.

Plasma and serum biosamples have been provided by Lungbiobank Heidelberg/BMBH in accordance with the regulations of the BMBH and the approval of the ethics committee of the University of Heidelberg. Analysis of clinical data and tissue and blood samples of the patient in this study was performed after informed consent and approval by the ethics committee of Heidelberg University (S-270/2001 and S-296/2016).

VARIANT INTERPRETATION {#s3}
======================

The median survival of *ALK*-rearranged non-small-cell lung cancer (ALK^+^ NSCLC) patients treated with tyrosine kinase inhibitors (TKIs) currently exceeds 5 yr, but clinical courses vary widely ([@MCS004630DIEC11]). Recent studies have demonstrated the association of this clinical heterogeneity with specific molecular tumor characteristics, such as the exact type of *ALK* fusion variant, including non-*EML4* fusions, as well as the presence of *TP53* and other mutations ([@MCS004630DIEC3],[@MCS004630DIEC4]; [@MCS004630DIEC14]; [@MCS004630DIEC15]; [@MCS004630DIEC5],[@MCS004630DIEC7]). Thus, broader molecular profiling of ALK^+^ NSCLC, using, for example, RNA-/DNA-NGS appears to provide information about several clinically relevant parameters that could be used to optimize therapies and personalized patient treatment beyond the readout obtainable from immunohistochemistry and FISH ([@MCS004630DIEC26]).

In the lung adenocarcinoma case presented here, a translocation of the *ALK* gene locus was initially detected by FISH analysis. Subsequent RNA sequencing identified fusion transcripts with exon 9 of *KLC1* fused to *ALK* exon 20 (K9--A20), which has been detected only at the RNA level in the past, without any information about TKI sensitivity ([@MCS004630DIEC25]). To the best of our knowledge, our study is the first report of the exact intronic double-strand breakpoints and the resulting interchromosomal rearrangement for a *KLC1--ALK* fusion, which we could identify using hybridization-based deep ctDNA sequencing ([Table 1](#MCS004630DIETB1){ref-type="table"}; [Fig. 1](#MCS004630DIEF1){ref-type="fig"}B). Our results show that the *KLC1--ALK* fusion of our patient encompasses the DNA sequence encoding the 5′-end part of *KLC1*, including the promoter domain, together with the sequence coding for the intracellular part of the ALK protein, including the entire tyrosine kinase domain, suggesting sensitivity to treatment with ALK inhibitors. Indeed, the patient showed a good response to crizotinib with partial tumor remission and is---to the best of our knowledge---the first *KLC1--ALK* NSCLC case successfully treated with ALK TKI in the literature.

###### 

Genomic findings

  Gene          Chr   HGVS DNA ref                                                      HGVS Protein ref   Variant type         Predicted effect                             Allele frequency   Target coverage   Mutation read count
  ------------- ----- ----------------------------------------------------------------- ------------------ -------------------- ------------------------------------------- ------------------ ----------------- ---------------------
  *KLC1--ALK*   2     t(2;14)(p23.1;32.33) (hg19 Chr 2:29,223,717:Chr 14:103,673,469)   n/a                *KLC1--ALK* fusion   Oncogenic, sensitivity to *ALK inhibitor*         8.09%              5860×                474
  *ALK*         2     c.3521T\>G                                                        p.F1174C           Substitution         Crizotinib resistance                             0.27%             10,316×               28
  *ALK*         2     c.3522C\>A                                                        p.F1174L           Substitution         Crizotinib resistance                             0.79%             10,192×               81
  *ALK*         2     c.3522C\>G                                                        p.P1174L           Substitution         Crizotinib resistance                             3.26%             10,192×               332
  *ALK*         2     c.3806G\>C                                                        p.G1269A           Substitution         Crizotinib resistance                             0.51%             16,190×               83

At the time of failure for any treatment, be it chemotherapy, crizotinib, or after cerebral radiotherapy ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}D, I1), disease progression was detectable in liquid biopsies as increasing VAF of the *KLC1--ALK* fusion and rising protein tumor markers. Moreover, at the time of cerebral disease progression with multiple new brain lesions under crizotinib ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}E,I3), ctDNA assessment identified four distinct mutations in the *ALK* kinase domain, which potentially cause the progression ([Table 1](#MCS004630DIETB1){ref-type="table"}; [Fig. 1](#MCS004630DIEF1){ref-type="fig"}B). Three out of the four (*ALK* c.3522C\>G, *ALK* c.3522C\>G/A, and c.3521T\>G) encode the p.F1174C/L variants, which are associated with resistance to ceritinib and crizotinib ([@MCS004630DIEC13]; [@MCS004630DIEC16]). The fourth mutation (*ALK* c.3806G\>C) encodes the p.G1269A variant, which is associated with resistance to crizotinib ([@MCS004630DIEC13]). Interestingly, the four secondary mutations show similar courses over time, suggesting a parallel evolution of multiple resistant clones with distinct molecular resistance mechanisms. Although Gainor et al. detected all these resistance mutations in tissue specimens obtained from progressing *EML4--ALK*-rearranged tumors, our report is the first to describe these mutations occurring simultaneously in ctDNA of a *KLC1--ALK* patient progressing under crizotinib. In line with this finding, recent proof-of-concept studies also demonstrated the feasibility of identifying and tracking resistance mutations to ALK inhibitors with serial liquid biopsies ([@MCS004630DIEC9]; [@MCS004630DIEC10]; [@MCS004630DIEC17]), illustrating the potential utility of plasma ctDNA genotyping in the clinical patient management in ALK^+^ NSCLC ([@MCS004630DIEC23]). Besides ALK^+^ NSCLC, several studies demonstrated the potential of ctDNA typing for cancer detection, molecular profiling, therapy monitoring, and identification of treatment resistance in various tumor entities ([@MCS004630DIEC19]; [@MCS004630DIEC1]; [@MCS004630DIEC27]; [@MCS004630DIEC8]). Finally, although imaging suggested stable disease after radiotherapy with remission of the cerebral lesions, rising ctDNA levels of the *KLC1--ALK* fusion and of all four secondary *ALK* point mutations suggested poor disease control. Importantly, this was accompanied by rising concentrations of both protein tumor markers CEA and CYFRA 21--1 in synchronous serum samples ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}C), and confirmed by the subsequent clinical course, which showed multifocal radiologic progression a few weeks later in conjunction with further increases in all ctDNA and protein markers.

Panel sequencing utilizes enrichment of specific loci and enables deep sequencing to detect recurrent hotspot or resistance mutations; however, it is limited to mutations within the target regions. In contrast, whole-genome or -exome sequencing of plasma DNA facilitates comprehensive molecular profiling, including de novo mutations and CNVs, but is only feasible for increased ctDNA fractions as the analytical sensitivity is limited by the relatively low coverage. Increasing the tumor-derived fraction of cell-free DNA could help to overcome this limitation and to improve the detection of somatic aberrations at lower sequencing depths ([@MCS004630DIEC18]). Here, we demonstrate a complementary use of targeted deep sequencing and low-coverage sWGS. In addition to mutation typing, we performed sWGS of cell-free DNA to assess CNV profiles at the genome-scale. Prior to crizotinib initiation, no CNVs were detected in the plasma sample of our patient. In contrast, remarkable alterations with fourfold t-MAD increase were detected at the end of treatment, including an amplification of a region on Chromosome 12 encompassing the TP53 regulator gene *MDM2* ([Fig. 1](#MCS004630DIEF1){ref-type="fig"}C,E). *MDM2* amplifications have been directly associated with worse prognosis and TKI resistance in *RET*-rearranged lung cancers ([@MCS004630DIEC12]; [@MCS004630DIEC24]), whereas impairment of TP53 function, as would be expected with MDM2 overexpression, is an important determinant of poor survival in ALK^+^ NSCLC, either at baseline or if acquired during the course of the disease ([@MCS004630DIEC15]; [@MCS004630DIEC6],[@MCS004630DIEC7]). Thus, although the presence of the amplification in the baseline cannot be excluded because of the overall low ctDNA fraction in this sample, the findings suggest that CNVs, including the *MDM2* amplification, might contribute to the progression of ALK^+^ NSCLC patients beyond secondary mutations in the ALK kinase domain.

SUMMARY {#s4}
=======

We report the first case of *KLC1--ALK*-rearranged lung adenocarcinoma responding to treatment with crizotinib and demonstrate the utility of multiple plasma and serum biomarkers for identification of *ALK* fusion partners and longitudinal disease monitoring in ALK^+^ NSCLC. At the time of treatment, failure under chemotherapy, crizotinib and cerebral radiotherapy, rising allelic frequencies of the *ALK* fusion, distinct *ALK* resistance mutations (in case of TKI), emerging CNV, and increasing concentrations of protein markers reflected the poor disease control and predicted the subsequent clinical deterioration, in part earlier and more reliably than radiologic findings. Our findings illustrate the potential clinical utility of noninvasive longitudinal molecular profiling for assessing remission status, exploring mechanisms of treatment failure, predicting subsequent clinical course, and dissecting dynamics of drug-resistant clones in ALK^+^ lung cancer.
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